Atul Butte's presentation to the Association of Medical School Pediatric Department Chairs #AMSPDC on March 3, 2018.
Some pre-publication data slides have been removed from this deck.
Atul Butte's presentation to the Association of Medical School Pediatric Department Chairs #AMSPDC on March 3, 2018.
Some pre-publication data slides have been removed from this deck.
The Uneven Future of Evidence-Based MedicineIda Sim
An Apple ResearchKit study enrolled 22,000 people in five days. A
study claims that Twitter can be used to identify depressed patients. A computer program crunches genomic data, the published literature, and electronic health record data to guide cancer treatment. The pace, the data sources, and the methods for generating medical evidence are changing radically. What will — what should — evidence-based medicine look like in a faster, personalized, data-dense tomorrow?
- Presented as the 3rd Annual Cochrane Lecture, October 2015 in Vienna, Austria.
Precision Medicine: Opportunities and Challenges for Clinical TrialsMedpace
The momentum and muscle behind "finding the right drug for the right patient at the right dose" has further escalated with President Barack Obama’s announcement of a $215 million dollar Precision Medicine Initiative earlier this year. In this webinar, Dr. Frank Smith will explore advances in precision medicine and how it is affecting clinical research. As a pediatric hematologist/oncologist, he will use his extensive clinical and research background as a backdrop for the discussion.
Topics will include:
The evolution of "personalized medicine" to "precision medicine"
How state-of-the-art molecular biology is creating new diagnostic and prognostic strategies
How these new strategies are helping inform the design of clinical trials
Case study: How precision medicine is improving clinical trials in hematology and oncology
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...Dexter Hadley
Lecture Objectives:
1) To use examples from my research to define and introduce the ideals of precision medicine and digital health. 2) To introduce how large scale population-wide analysis of data can be used to facilitate these two ideals. 3) To introduce how freely available open data can be used to facilitate these two ideals. 4) To show how mobile technology can be used to facilitate these two ideals.
The Uneven Future of Evidence-Based MedicineIda Sim
An Apple ResearchKit study enrolled 22,000 people in five days. A
study claims that Twitter can be used to identify depressed patients. A computer program crunches genomic data, the published literature, and electronic health record data to guide cancer treatment. The pace, the data sources, and the methods for generating medical evidence are changing radically. What will — what should — evidence-based medicine look like in a faster, personalized, data-dense tomorrow?
- Presented as the 3rd Annual Cochrane Lecture, October 2015 in Vienna, Austria.
Precision Medicine: Opportunities and Challenges for Clinical TrialsMedpace
The momentum and muscle behind "finding the right drug for the right patient at the right dose" has further escalated with President Barack Obama’s announcement of a $215 million dollar Precision Medicine Initiative earlier this year. In this webinar, Dr. Frank Smith will explore advances in precision medicine and how it is affecting clinical research. As a pediatric hematologist/oncologist, he will use his extensive clinical and research background as a backdrop for the discussion.
Topics will include:
The evolution of "personalized medicine" to "precision medicine"
How state-of-the-art molecular biology is creating new diagnostic and prognostic strategies
How these new strategies are helping inform the design of clinical trials
Case study: How precision medicine is improving clinical trials in hematology and oncology
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...Dexter Hadley
Lecture Objectives:
1) To use examples from my research to define and introduce the ideals of precision medicine and digital health. 2) To introduce how large scale population-wide analysis of data can be used to facilitate these two ideals. 3) To introduce how freely available open data can be used to facilitate these two ideals. 4) To show how mobile technology can be used to facilitate these two ideals.
The $1000 genome is here, and the fundamental problems have shifted... it is no longer about shrinking the cost of sequencing but the explosive growth of big data: the downstream analytics with rapidly evolving parameters, data sources and formats; the storage, movement and management of massive datasets and workloads, and the challenge of articulating the results and translating the latest findings directly into improving patient outcomes. This presentation talks to the work Intel Corp. is doing with it's partners to make research and clinical genomics mainstream - "Taking Precision Medicine Mainstream."
Elsevier Medical Graph – mit Machine Learning zu Precision MedicineRising Media Ltd.
Elsevier Health Analytics entwickelt den Medical Knowledge Graph, welcher Korrelationen zwischen Krankheiten und zwischen Krankheiten und Behandlungen darstellt. Auf einem Gesamtdatensatz von sechs Millionen anonymisierten Patienten, beobachtbar über sechs Jahre, haben wir über 2000 Modelle erstellt, welche die Entwicklung von Krankheiten prognostizieren. Jedes Modell ist adjustiert für mehr als 3000 Kovariablen. Dazu kam ein Boosting Algorithmus mit Variablenselektion zum Einsatz. Die Betas der selektierten Variablen wurden extrahiert, getestet hinsichtlich Kausalität und Signifikanz, und daraus wurde die erste Version des Medical Graphen mit über 2000 Krankheitsknoten und 25.000 Effekt-Kanten gebaut. Der Graph wird aktuell in der Praxis getestet, mit dem Ziel, dem Arzt eine patienten-individuelle Entscheidungsunterstützung für die Behandlung zu geben.
Genomic Medicine: Personalized Care for Just PenniesHealth Catalyst
In April 2003, the Human Genome Project was completed and scientists gained the ability to read the entire genetic blueprint for human beings. Since that time, the cost of gene sequencing has fallen from $100 million to $1,000. By 2020, the cost is expected to be mere pennies. Using the power of genomes scientists have found genomic defects for more than 5,000 inherited diseases and are on track to uncover 4,000 more. The implications for treatment of disease are also vast. In the future, clinicians will be able to use genomic-powered personalized medicine to treat patients on an individual basis knowing exactly how their genes will react to treatments and what the best course of action will be.
National Cancer Data Ecosystem and Data SharingWarren Kibbe
Grand Rounds at the Siteman Cancer Center at Washington University. Highlighting the Genomic Data Commons and the National Cancer Data Ecosystem defined by the Cancer Moonshot Blue Ribbon Panel
Cancer Moonshot, Data sharing and the Genomic Data CommonsWarren Kibbe
Gave the inaugural Informatics Grand Rounds at City of Hope on September 8th. NIH Commons, Genomic Data Commons, NCI Cloud Pilots, Cancer Moonshot and rationale for changing incentives around data sharing all discussed.
Summary: At The Economist’s War on Cancer 2015 event on 20 October 2015 (http://www.economist.com/events-conferences/emea/war-cancer-london), EY’s Silvia Ondategui-Parra joined the panel discussion “The patient/payer debate—balancing clinical need and affordability.” The panel explored the ongoing tension between the soaring cost of cancer drugs and governments’ ability to fund them and raised the question, do we need an entirely new pricing model? This EY infographic was developed to highlight some of the key trends driving the debate.
Remote presentation by Atul Butte at the NSTC Interagency Working Group on Biological Data Sharing on 2019-06-12.
The working group is charged by the National Science and Technology Council to develop a road map to enable robust sharing and maximize reuse of biological data, identifying opportunities for interagency coordination, and academic, industrial, and international partnerships. The workshop will bring together a diverse community of government, academic, and industrial stakeholders to identify key bottlenecks and challenges that interfere with the open exchange of information and to identify potential solutions that will accelerate biological science research.
The Learning Health System: Thinking and Acting Across ScalesPhilip Payne
A Learning Health System (LHS) can be defined as an environment in which knowledge generation processes are embedded into daily clinical practice in order to continually improve the quality, safety, and outcomes of healthcare delivery. While still largely an aspirational goal, the promise of the LHS is a future in which every patient encounter is an opportunity to learn and improve that patient’s care, as well as the care their family and broader community receives. The foundation for building such an LHS can and should be the Electronic Health Record (EHR), which provides the basis for the comprehensive instrumentation and measurement of clinical phenotypes, as well as a means of delivering new evidence at the patient- and population levels. In this presentation, we will explore the ways in which such EHR-derived phenotypes can be combined with complementary data across a spectrum from biomolecules to population level trends, to both generate insights and deliver such knowledge in the right time, place, and format, ultimately improving clinical outcomes and value.
Health IT Summit Beverly Hills 2014 – Case Study “The Progression of Predictive Analytics: The Rothman Index” with Mark Headland, VP & CIO, Children’s Hospital of Orange County
EuroBioForum 2013 - Day 2 | Mark PoznanskyEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
Ontario Genomics Institute, Canada:
Innovative Research, Innovative Translation
Dr Mark Poznansky
President and CEO Ontario Genomics Institute
=======================================
http://www.eurobioforum.eu
Data sharing drivers in precision oncology, biomedical research, and healthcare. Accelerating discovery, innovation, providing credit for all stakeholders - patients, researchers, care providers, payers.
discussing all aspects of evidence based medicine, Introduction
History of EBM
Need of EBM
Steps to practice
Discussion - advantages/disadvantages/critical analysis
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
1. Translating a Trillion Points of Data into
New Diagnostics, Therapeutics, and a
New Precise Medical System
atul.butte@ucsf.edu
@atulbutte
Atul Butte, MD, PhD
Director, Institute for Computational
Health Sciences
University of California, San Francisco
5. Preeclampsia: large cause of maternal and fetal death
• Incidence
• 5-8% of all pregnancies in the U.S. and worldwide
• 4.1 million births in the U.S. in 2009
• Up to 300K cases of preeclampsia annually in the U.S.
• Mortality
• Responsible for 18% of all maternal deaths in the U.S.
• Maternal death in 56 out of every 100,000 live births in US
• Neonatal death in 71 out of every 100,000 live births in US
• Cost
• $20 billion in direct costs in the U.S annually
• Average hospital stay of 3.5 days
• Need for a more specific diagnostic
Linda Liu
Bruce Ling
Matt Cooper
6. New blood markers for preeclampsia
Linda Liu
Bruce Ling
Matt Cooper
@MarchofDimes
bit.ly/preeclamp
7. Need a
diagnostic for
preeclampsia
Public big data
available
March of Dimes
Center for
Prematurity
Research
Data analyzed,
diagnostic
designed
SPARK grant
($50k)
Life Science
Angels, other
seed investors
($2 million)
@CarmentaBio
progenity.com
bit.ly/carm_prog
9. Psychiatric Drug Imipramine Shows Significant Activity
Against Small Cell Lung Cancer
Vehicle control Imipramine
p53/Rb/p130
triple knockout
model of SCLC
Mice dosed after
tumor formation
Joel Dudley
Nadine Jahchan
Julien Sage
Alejandro Sweet-Cordero
Joel Neal
@NuMedii
10. Need more drugs
for more diseases
Public big data
available
NIH funding
Data analyzed,
method designed
Company launched,
ARRA, StartX,
Stanford license,
first deal
Claremont Creek,
Lightspeed
($5.5 million)
@NuMedii
12. Build the strongest team in the world in
biomedical computation and health data analytics
• Launched in 2015
• Academic affinity home for 29 faculty and staff
• Research and development (and spin out technologies)
• Develop new educational plans
• Recruit the best computational/informatics faculty to UCSF
• Organize infrastructure and operations
• Build and use our new data assets for precision medicine
15. Combining healthcare data from across the
six University of California medical schools and systems
Clinical Data Warehouse
A Big UC Healthcare Data Analytics Platform
16. What could we do with raw clinical data?
• Mobile health researcher at UCSD can enable patients to contribute data for research
• Community activist and researcher UC Merced can study environmental factors
contributing to health and disease
• Transplant patient at UC Irvine can download all their data across UC Health
• App designer at UC Riverside can show patients their choices with chronic disease
• CMO at UCSF can build predictive models for readmission, test, share across UC Health
• AI researcher at UC Berkeley can build deep-learning models for image-based
diagnostics
• Health services researcher at UC Davis can build predictive models for drug efficacy, and
maybe enable pay-for-performance
• Cancer genomics researcher at UCSC can study all our clinical cancer genomes
17.
18. Take home points:
• Plenty of high-quality data already available:
some public, some private
• Don’t wait for perfection; data always
getting better
• Use and intersect data to ask new questions,
to innovative new diagnostics and drugs
• Academia and industry are compatible: the science
can and will continue in industry
19. UC Clinical Data Warehouse Team
Executive Team
• Atul Butte
• Joe Bengfort
• Michael Pfeffer
• Tom Andriola
Steering Committee
• Irfan Chaudhry
• Mohammed Mahbouba
• Lisa Dahm
• David Dobbs
• Kent Andersen
• Ralph James
• Jennifer Holland
• Eugene Lee
ETL Team
• Albert Dugan
• Tony Choe
• Michael Sweeney
• Timothy Satterwhite
• Ayan Patel
• Niranjan Wagle
• Ralph James
• Joseph Dalton
Data Harmonization
• Dana Ludwig
Data Quality
• Momeena Ali
• Jodie Nygaard
Epic
• Kevin Ames
• Ben Jenkins
• Steve Gesualdo
Business Analyst
• Ankeeta Shukla
Hardware
• Sandeep Chandra
• Jeff Love
• Scott Bailey
• Kwong Law
• Pallav Saxena
Support
• Jack Stobo
• Michael Blum
• Sam Hawgood
20. Collaborators
• Jeff Wiser, Patrick Dunn, Mike Atassi / Northrop Grumman
• Ashley Xia and Quan Chen / NIAID
• Takashi Kadowaki, Momoko Horikoshi, Kazuo Hara, Hiroshi Ohtsu / U Tokyo
• Kyoko Toda, Satoru Yamada, Junichiro Irie / Kitasato Univ and Hospital
• Shiro Maeda / RIKEN
• Alejandro Sweet-Cordero, Julien Sage / Pediatric Oncology
• Mark Davis, C. Garrison Fathman / Immunology
• Russ Altman, Steve Quake / Bioengineering
• Euan Ashley, Joseph Wu, Tom Quertermous / Cardiology
• Mike Snyder, Carlos Bustamante, Anne Brunet / Genetics
• Jay Pasricha / Gastroenterology
• Rob Tibshirani, Brad Efron / Statistics
• Hannah Valantine, Kiran Khush/ Cardiology
• Ken Weinberg / Pediatric Stem Cell Therapeutics
• Mark Musen, Nigam Shah / National Center for Biomedical Ontology
• Minnie Sarwal / Nephrology
• David Miklos / Oncology
21. Support
Admin and Tech Staff
• Mary Lyall
• Mounira Kenaani
• Kevin Kaier
• Boris Oskotsky
• University of California, San Francisco
• NIH: NIAID, NLM, NIGMS, NCI; NIDDK, NHGRI, NIA, NHLBI, NCATS
• March of Dimes
• Juvenile Diabetes Research Foundation
• Hewlett Packard Foundation
• Howard Hughes Medical Institute
• California Institute for Regenerative Medicine
• Luke Evnin and Deann Wright (Scleroderma Research Foundation)
• Clayville Research Fund
• PhRMA Foundation
• Tarangini Deshpande
• Kimayani Butte
• Sam Hawgood
• Keith Yamamoto
• Isaac Kohane